1. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension 
Charles Khouri, PharmD, Marion Lepelley, PharmD, Matthieu Roustit, PharmD, François Montastruc, MD, Marc Humbert, MD, Jean-Luc Cracowski, MD 
CHEST 
DOI: /j.chest
Copyright © 2017 American College of Chest Physicians Terms and Conditions

2. Figure 1
Study design. ADE = adverse drug event; ADR = adverse drug reaction; MedDRA = Medical Dictionary for Regulatory Activities; WHO = World Health Organization.
CHEST DOI: ( /j.chest )
Copyright © 2017 American College of Chest Physicians Terms and Conditions

3. Figure 2 Flowchart of the meta-analysis.
CHEST DOI: ( /j.chest )
Copyright © 2017 American College of Chest Physicians Terms and Conditions

4. Figure 3
Forest plot comparing the meta-analysis and the disproportionality analysis. GRADE quality of evidence includes moderate (○⊗⊗), low (○○⊗⊗), and very low (○○○⊗). GRADE = Grading of Recommendation Assessment, Development and Evaluation; I2 = heterogeneity; IRR = incidence rate ratio; n = No. of studies in the subgroup; NNH = number needed to harm (patient-years); Proportion ADRs = proportion of adverse drug reactions of interest per overall number of adverse drug reactions in VigiBase for one given drug; PRR = proportional reported ratio. See Figure 1 legend for expansion of other abbreviation.
CHEST DOI: ( /j.chest )
Copyright © 2017 American College of Chest Physicians Terms and Conditions

5. Figure 4
Results of disproportionality analysis according to the time on the market.
CHEST DOI: ( /j.chest )
Copyright © 2017 American College of Chest Physicians Terms and Conditions